{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:11:32Z","timestamp":1790856692720,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Although lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are associated with cardiovascular events, Lp-PLA2 is physically linked to LDL cholesterol (LDL-C). Whether measures of Lp-PLA2 mass or activity continue to predict risk after LDL-C reduction by statin therapy is uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Lp-PLA2 mass concentration and activity were evaluated at baseline and after treatment in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial comparing rosuvastatin 20 mg to placebo among 17 802 men and women without cardiovascular disease or diabetes at study entry. The relationships of Lp-PLA2 mass and activity with risk of future vascular events were evaluated in the placebo and rosuvastatin groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Before randomization, levels of Lp-PLA2 mass and activity correlated moderately with each other and with LDL-C. The magnitude of these correlations increased after statin therapy. Rosuvastatin reduced Lp-PLA2 mass by 33.8%, Lp-PLA2 activity by 33.2%, and LDL-C by 48.7% (all P &amp;lt; 0.0001). Among those study participants allocated to placebo, increasing quartiles of Lp-PLA2 activity (Ptrend = 0.04) but not Lp-PLA2 mass (Ptrend = 0.92) were associated with incident cardiovascular events after adjustment for LDL-C and conventional risk factors. Comparable analyses conducted among those allocated to rosuvastatin revealed no significant relationship between Lp-PLA2 levels and subsequent vascular events. The ability of rosuvastatin to reduce vascular events was not significantly modified by baseline Lp-PLA2 level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Among JUPITER trial participants allocated to placebo, levels of Lp-PLA2 activity, but not mass, were associated with cardiovascular risk. However, Lp-PLA2 no longer predicted risk or modified clinical outcomes when participants were treated with rosuvastatin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2011.180281","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T02:52:52Z","timestamp":1331779972000},"page":"877-886","source":"Crossref","is-referenced-by-count":70,"title":["Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial"],"prefix":"10.1093","volume":"58","author":[{"given":"Paul M","family":"Ridker","sequence":"first","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean G","family":"MacFadyen","sequence":"first","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Wolfert","sequence":"first","affiliation":[{"name":"diaDexus, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"2020022705132077700_B1","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet"},{"key":"2020022705132077700_B2","unstructured":"The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). http:\/\/clinicaltrials.gov\/ct2\/show\/nct00799903 (Accessed April 2010)"},{"key":"2020022705132077700_B3","unstructured":"The Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction 52 Trial (SOLID-TIMI 52). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01000727 (Accessed April 2010)."},{"key":"2020022705132077700_B4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","article-title":"Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target","volume":"25","author":"Zalewski","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020022705132077700_B5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2796.2010.02258.x","article-title":"Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality","volume":"268","author":"Heart Protection Study Collaborative Group","year":"2010","journal-title":"J Intern Med"},{"key":"2020022705132077700_B6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation"},{"key":"2020022705132077700_B7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/01.ATV.0000148322.89911.44","article-title":"Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study","volume":"25","author":"Iribarren","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020022705132077700_B8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2007.10.048","article-title":"Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study","volume":"51","author":"Daniels","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2020022705132077700_B9","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.0000222983.73369.c8","article-title":"Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress","volume":"26","author":"Koenig","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020022705132077700_B10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2009.10.041","article-title":"Lipoprotein-associated phospholipase A2, an inflammatory biomarker, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly (PROSPER)","volume":"210","author":"Caslake","year":"2010","journal-title":"Atherosclerosis"},{"key":"2020022705132077700_B11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.atherosclerosis.2009.09.021","article-title":"Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study","volume":"209","author":"Jenny","year":"2010","journal-title":"Atherosclerosis"},{"key":"2020022705132077700_B12","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1161\/CIRCULATIONAHA.110.936393","article-title":"Lipoprotein-associated and secreted phospholipase A2 in cardiovascular disease","volume":"122","author":"Mallat","year":"2010","journal-title":"Circulation"},{"key":"2020022705132077700_B13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/ATVBAHA.107.142679","article-title":"Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects","volume":"27","author":"Persson","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020022705132077700_B14","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.105.612630","article-title":"Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 trial","volume":"113","author":"O'Donoghue","year":"2006","journal-title":"Circulation"},{"key":"2020022705132077700_B15","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2020022705132077700_B16","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"2020022705132077700_B17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"2020022705132077700_B18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"key":"2020022705132077700_B19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2005.05.006","article-title":"The effect of statin therapy on lipoprotein associated phospholipase A2 levels","volume":"182","author":"Albert","year":"2005","journal-title":"Atherosclerosis"},{"key":"2020022705132077700_B20","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1161\/ATVBAHA.107.147280","article-title":"Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2","volume":"27","author":"Saougas","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020022705132077700_B21","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1172\/JCI118733","article-title":"Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase","volume":"97","author":"Stafforini","year":"1996","journal-title":"J Clin Invest"},{"key":"2020022705132077700_B22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00439-008-0587-4","article-title":"Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study","volume":"125","author":"Hou","year":"2009","journal-title":"Hum Genet"},{"key":"2020022705132077700_B23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1538-7836.2008.03216.x","article-title":"Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study)","volume":"7","author":"Hoffmann","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2020022705132077700_B24","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1210\/jc.2006-0116","article-title":"The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men","volume":"91","author":"Jang","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020022705132077700_B25","doi-asserted-by":"crossref","first-page":"e1000928","DOI":"10.1371\/journal.pgen.1000928","article-title":"Genome-wide association study of Lp-PLA2 activity and mass in the Framingham Heart Study","volume":"6","author":"Suchindran","year":"2010","journal-title":"PLoS Genet"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/5\/877\/32658409\/clinchem0877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/5\/877\/32658409\/clinchem0877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T05:15:03Z","timestamp":1582780503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/58\/5\/877\/5620676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,1]]},"published-print":{"date-parts":[[2012,5,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2011.180281","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,5,1]]},"published":{"date-parts":[[2012,5,1]]}}}